IN THE NEWS
5/16/08 - 2008 Mira Award Winners & Finalists
3/31/08—Dr. Malkas to present: “Moving Technology from the Academic to Business Setting”
2/28/08 - Bill Puts Biomarker Discovery at Heart of Attack on Ovarian Cancer
1/29/08 - Prolog invests in Indianapolis-based CS-Keys
1/29/08 - Indianapolis-based cancer researchers close on $6.25 million of Series A financing
1/25/08 - Ceres Venture Fund Invests in Cancer-Specific Biomarker Company CS-Keys, Inc.
6/26/07—Dr. Linda Malkas to speak at Innovention Conference
4/9/07—30 Midwest Firms to Present This Week at InvestMidwest
4/3/07—TechPoint Announces Mira Awards Nominations
2/13/07—CS-Keys in Forefront of Fight Against Cancer
1/24/07—Indiana Life Sciences Leaders Form CEO Roundtable
1/22-28/07—Executive lunches feed search for new biotech ideas
CHANGING THE WAY PATHOLOGISTS SEE CANCER CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment. The discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective.
|
CS-Keys is developing products to aid in the detection of breast cancer at its earliest stages including in conditions such as DCIS.  |
Barrett's esophagus may be a precursor to cancer in some patients. CS-Keys may help physicians identify patients at greatest risk.
 |
CS-Keys technology appears to apply well to the following:
|